1. Tramacere, I, Del Giovane, C, Salanti, G, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: A network meta-analysis. Cochrane Datab Syst Rev 2015; 2015: CD14011381.
Google Scholar2. Ng, HS, Zhu, F, Kingwell, E, et al. Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting. Expert Rev Neurother 2020; 21: 131–140.
Google Scholar | Crossref | Medline3. Marrie, RA, Elliott, L, Marriott, J, et al. Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology 2014; 83: 929–937.
Google Scholar | Crossref | Medline | ISI4. Nicholas, J, Boster, A, Wu, N, et al. Comparison of disease-modifying therapies for the management of multiple sclerosis: Analysis of healthcare resource utilization and relapse rates from US insurance claims data. Pharmacoecon Open 2018; 2(1): 31–41.
Google Scholar | Crossref | Medline5. Bonafede, MM, Johnson, BH, Watson, C. Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the US. Clinicoecon Outcomes Res 2013; 6: 11–20.
Google Scholar | Crossref | Medline6. Al-Sakran, L, Marrie, RA, Blackburn, D, et al. Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: A retrospective cohort study. BMJ Open 2019; 9: e033599.
Google Scholar | Crossref | Medline7. Pirttisalo, AL, Sipilä, JOT, Soilu-Hänninen, M, et al. Adult hospital admissions associated with multiple sclerosis in Finland in 2004–2014. Ann Med 2018; 50(4): 354–360.
Google Scholar | Crossref | Medline8. Statistics Canada . Census profile, 2016 census, 2017, https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/index.cfm?Lang=E (accessed 1 February 2021).
Google Scholar9. British Columbia Ministry of Health [Creator] . Medical services plan (MSP) payment information file: V2—Population data BC [Publisher]. Data Extract. MOH, 2017, http://www.popdata.bc.ca/data
Google Scholar10. Canadian Institute for Health Information [Creator] . Discharge abstract database (hospital separations): V2—Population data BC [Publisher]. Data extract. MOH, 2017, http://www.popdata.bc.ca/data
Google Scholar11. British Columbia Ministry of Health [Creator] . Consolidation file (MSP registration & premium billing): V2. Population Data BC [Publisher]. Data extract. MOH, 2017, http://www.popdata.bc.ca/data
Google Scholar12. BC and Vital Statistics Agency [Creator] . Vital statistics deaths: V2. Population data BC [Publisher]. Data extract. BC Vital Statistics Agency, 2017, http://www.popdata.bc.ca/data
Google Scholar13. BC and Ministry of Health [Creator] . PharmaNet: V2. BC Ministry of Health [Publisher]. Data Extract. Data Stewardship Committee, 2017, http://www.popdata.bc.ca/data
Google Scholar14. Marrie, RA, Yu, N, Blanchard, J, et al. The rising prevalence and changing age distribution of multiple sclerosis in Manitoba. Neurology 2010; 74: 465–471.
Google Scholar | Crossref | Medline | ISI15. Canadian Institute for Health Information Statistics Canada . Health Indicators 2013, 2013, https://www.cihi.ca/sites/default/files/document/health-indicators-2013-en.pdf (accessed 3 March 2021).
Google Scholar16. Marrie, RA, Bernstein, CN, Peschken, CA, et al. Intensive care unit admission in multiple sclerosis: Increased incidence and increased mortality. Neurology 2014; 82: 2112–2119.
Google Scholar | Crossref | Medline | ISI17. Wijnands, JMA, Zhu, F, Kingwell, E, et al. Disease-modifying drugs for multiple sclerosis and infection risk: A cohort study. J Neurol Neurosurg Psychiatry 2018; 89(10): 1050–1056.
Google Scholar | Crossref | Medline18. Graham, DJ, Staffa, JA, Shatin, D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585–2590.
Google Scholar | Crossref | Medline | ISI19. Evans, C, Zhu, F, Kingwell, E, et al. Association between beta-interferon exposure and hospital events in multiple sclerosis. Pharmacoepidemiol Drug Saf 2014; 23(11): 1213–1222.
Google Scholar | Crossref | Medline20. Rae-Grant, A, Day, GS, Marrie, RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis —Report of the guideline development, dissemination, and implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90: 777–788.
Google Scholar | Crossref | Medline21. O’Connor, PW, Lublin, FD, Wolinsky, JS, et al. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol 2013; 260(10): 2472–2480.
Google Scholar | Crossref | Medline | ISI22. Weinstock-Guttman, B, Galetta, SL, Giovannoni, G, et al. Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol 2012; 259(5): 898–905.
Google Scholar | Crossref | Medline23. Simbrich, A, Thibaut, J, Khil, L, et al. Drug-use patterns and severe adverse events with disease-modifying drugs in patients with multiple sclerosis: A cohort study based on German claims data. Neuropsychiatr Dis Treat 2019; 15: 1439–1457.
Google Scholar | Crossref | Medline24. Rommer, PS, Zettl, UK, Kieseier, B, et al. Requirement for safety monitoring for approved multiple sclerosis therapies: An overview. Clin Exp Immunol 2014; 175(3): 397–407.
Google Scholar | Crossref | Medline25. Sanchirico, M, Caldwell-Tarr, A, Mudumby, P, et al. Treatment patterns, healthcare resource utilization, and costs among Medicare patients with multiple sclerosis in relation to disease-modifying therapy and corticosteroid treatment. Neurol Ther 2019; 8(1): 121–133.
Google Scholar | Crossref | Medline26. Koch-Henriksen, N, Magyari, M, Sellebjerg, F, et al. A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. Mult Scler 2017; 23(2): 234–241.
Google Scholar | SAGE Journals | ISI27. Lanzillo, R, Carotenuto, A, Moccia, M, et al. A longitudinal real-life comparison study of natalizumab and fingolimod. Acta Neurol Scand 2017; 136(3): 217–222.
Google Scholar | Crossref | Medline28. Lorscheider, J, Benkert, P, Lienert, C, et al. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis. Mult Scler 2018; 24(6): 777–785.
Google Scholar | SAGE Journals | ISI29. Kalincik, T, Horakova, D, Spelman, T, et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol 2015; 77(3): 425–435.
Google Scholar | Crossref | Medline30. Sanofi Genzyme A and Division of Sanofi-Aventis Canada Inc . LEMTRADA (Alemtuzumab 12mg/1.2mL) product monograph [online], 2020, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html (accessed 11 January 2021).
Google Scholar31. Sanofi Genzyme A and Division of Sanofi-Aventis Canada Inc . AUBAGIO (Teriflunomide tablets 14 mg) product monograph [online], 2020, https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html (accessed 11 January 2021).
Google Scholar32. Wians, FH . Clinical laboratory tests: Which, why, and what do the results mean? Lab Med 2009; 40: 105–113.
Google Scholar | Crossref | ISI33. Kalincik, T, Kubala Havrdova, E, Horakova, D, et al. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry 2019; 90(4): 458–468.
Google Scholar | Crossref | Medline34. Jain, N, Bhatti, MT. Fingolimod-associated macular edema: Incidence, detection, and management. Neurology 2012; 78: 672–680.
Google Scholar | Crossref | Medline | ISI35. Gasim, M, Bernstein, CN, Graff, LA, et al. Adverse psychiatric effects of disease-modifying therapies in multiple sclerosis: A systematic review. Mult Scler Relat Disord 2018; 26: 124–156.
Google Scholar | Crossref | Medline36. Li, R, Sun, X, Shu, Y, et al. Sex differences in outcomes of disease-modifying treatments for multiple sclerosis: A systematic review. Mult Scler Relat Disord 2017; 12: 23–28.
Google Scholar | Crossref | Medline37. Houtchens, MK, Bove, R. A case for gender-based approach to multiple sclerosis therapeutics. Front Neuroendocrinol 2018; 50: 123–134.
Google Scholar | Crossref | Medline